CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...

The stock of biotechnology firm Intellia Therapeutics has experienced a severe downturn after US regulators imposed a ...

Ark Invest Block Inc shares purchase totals $30.9M across ARKK, ARKW, and ARKF, as Cathie Wood boosts exposure to crypto and ...

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

Shares of CleanSpark, Inc. (NASDAQ:CLSK) are trading higher Wednesday after the Bitcoin (CRYPTO: BTC) miner announced ...